Skip to main content
NCBI home page
Quality & Safety in Health Care logoLink to Quality & Safety in Health Care
. 2005 Aug;14(4):246–250. doi: 10.1136/qshc.2004.012781

Benefits and harms of direct to consumer advertising: a systematic review

S Gilbody 1, P Wilson 1, I Watt 1
PMCID: PMC1744049  PMID: 16076787

Abstract

Background: Direct to consumer advertising is increasingly used by the pharmaceutical industry, but its benefits and harms have yet to be summarised in a comprehensive and rigorous manner.

Methods: A systematic review was conducted of robust evaluations of the impact (positive and negative) of direct to consumer advertising. A broad range of databases and data sources (including Cinahl, Embase, HMIC, HSRProj, Medline, PsycInfo, and the internet) were searched from inception to 2004.

Results: From 2853 citations only four reports were found that met the strict inclusion criteria and provided usable results. Direct to consumer advertising is associated with increased prescription of advertised products and there is substantial impact on patients' request for specific drugs and physicians' confidence in prescribing. No additional benefits in terms of health outcomes were demonstrated.

Discussion: Direct to consumer advertising is banned in most countries, and the research evidence tends to support the negative impact that is feared by those who support a legislative ban. Further research is needed into the clinical and economic impact of direct to consumer advertising in healthcare systems.

Full Text

The Full Text of this article is available as a PDF (87.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. 't Jong Geert W., Stricker Bruno H. Ch, Sturkenboom Miriam C. J. M. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ. 2004 Feb 26;328(7445):931–931. doi: 10.1136/bmj.38007.711481.F7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonaccorso Silvia N., Sturchio Jeffrey L. For and against: Direct to consumer advertising is medicalising normal human experience: Against. BMJ. 2002 Apr 13;324(7342):910–911. doi: 10.1136/bmj.324.7342.910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burton Bob. Drug industry to fight New Zealand's move to ban direct to consumer advertising. BMJ. 2004 May 1;328(7447):1036–1036. doi: 10.1136/bmj.328.7447.1036-d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hoffman J. R., Wilkes M. Direct to consumer advertising of prescription drugs. An idea whose time should not come. BMJ. 1999 May 15;318(7194):1301–1302. doi: 10.1136/bmj.318.7194.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mintzes Barbara, Barer Morris L., Kravitz Richard L., Bassett Ken, Lexchin Joel, Kazanjian Arminée, Evans Robert G., Pan Richard, Marion Stephen A. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ. 2003 Sep 2;169(5):405–412. [PMC free article] [PubMed] [Google Scholar]
  6. Mintzes Barbara, Barer Morris L., Kravitz Richard L., Kazanjian Arminée, Bassett Ken, Lexchin Joel, Evans Robert G., Pan Richard, Marion Stephen A. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ. 2002 Feb 2;324(7332):278–279. doi: 10.1136/bmj.324.7332.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mintzes Barbara. For and against: Direct to consumer advertising is medicalising normal human experience: For. BMJ. 2002 Apr 13;324(7342):908–909. doi: 10.1136/bmj.324.7342.908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Moher D., Cook D. J., Eastwood S., Olkin I., Rennie D., Stroup D. F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999 Nov 27;354(9193):1896–1900. doi: 10.1016/s0140-6736(99)04149-5. [DOI] [PubMed] [Google Scholar]
  9. Moynihan Ray, Heath Iona, Henry David. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002 Apr 13;324(7342):886–891. doi: 10.1136/bmj.324.7342.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Moynihan Ray. The marketing of a disease: female sexual dysfunction. BMJ. 2005 Jan 22;330(7484):192–194. doi: 10.1136/bmj.330.7484.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rosenthal Meredith B., Berndt Ernst R., Donohue Julie M., Frank Richard G., Epstein Arnold M. Promotion of prescription drugs to consumers. N Engl J Med. 2002 Feb 14;346(7):498–505. doi: 10.1056/NEJMsa012075. [DOI] [PubMed] [Google Scholar]
  13. Weissman Joel S., Blumenthal David, Silk Alvin J., Newman Michael, Zapert Kinga, Leitman Robert, Feibelmann Sandra. Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff (Millwood) 2004 Jan-Jun;Suppl Web Exclusives:W4–219-33. doi: 10.1377/hlthaff.w4.219. [DOI] [PubMed] [Google Scholar]
  14. Wolfe Sidney M. Direct-to-consumer advertising--education or emotion promotion? N Engl J Med. 2002 Feb 14;346(7):524–526. doi: 10.1056/NEJM200202143460713. [DOI] [PubMed] [Google Scholar]

Articles from Quality & safety in health care are provided here courtesy of BMJ Publishing Group

RESOURCES